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INTRODUCTION 
Despite of tremendous innovations in drug delivery, the 
oral route remains the preferred route for administration of 
therapeutic agents because of accurate dosage, low cost 
therapy, self medication, non invasive method and ease of 
administration leading to high level of patient compliance 
1. However, traditional tablets and capsules administered 
with a glass of water may be inconvenient or impractical 
for some geriatric patients because of changes in various 
physiological and neurological conditions associated with 
aging including difficulty in swallowing/dysphagia, hand 
tremors, deterioration in their eyesight, hearing, memory, 
risk of choking in addition to change in taste and smell. 
Solid dosage forms also present significant administration 
challenges in other patient groups, such as children, 
mentally challenged, bed ridden and uncooperative 
patients. Paediatric patients may suffer from ingestion 
problems as a result of underdeveloped muscular and 
nervous control. Moreover, patients travelling with little or 
no access to water, limit utility of orally administered 
conventional tablets or capsules. 
Therefore, to cater the needs of such patients, recent 
advancements in technology have resulted in development 
of viable dosage alternatives popularly known as orally 
disintegrating tablets (ODTs)[1,2].During the past decade, 
the FDT (fast dissolving tablet) technology, which makes 
tablets dissolve or disintegrate in the mouth without 
additional water intake, has drawn a great deal of attention. 
The technology is also referred to as fast disintegrating 
tablet, fast dispersing tablet, rapid dissolve tablet, rapid 
melt tablet, quick disintegrating tablet, and orally 
disintegrating tablet. The FDT formulation is defined by 
the Food and Drug Administration (FDA) as ‘‘a solid 
dosage form containing medicinal substances which 
disintegrates rapidly, usually within a matter of 
seconds, when placed upon the tongue’’. The tablets 
disintegrate into smaller granules or melt in the mouth 
from a hard solid structure to a gel like structure, allowing 
easy swallowing by the patients. The disintegration time 
for those tablets varies from a few seconds to more than a 
minute 2,3.  
Administration of FDTs is different from conventional 
tablets, and the FDTs should have several unique 
properties to accommodate the rapid disintegration 
time.They should dissolve or disintegrate in the mouth 
without water or with a very small amount of water as the 
disintegration fluid is the patient‟s saliva. The 
disintegrated tablet should become a soft paste or liquid 
suspension, which provides good mouth feel and enables 
smooth swallowing. „„Fast dissolution‟‟ or „„fast 
disintegration‟‟ typically requires dissolution or 
disintegrationof a tablet within one minute.1,2 
Significance of ODTs 
4,5
 
ODTs offer dual advantages of solid dosage forms and 
liquid dosage forms along with special Features which 
include: 
Accurate dosing: Being unit solid dosage forms, 
provide luxury of accurate dosing, easy portability and 
manufacturing, good physical and chemical stability and 
an ideal alternative for pediatric and geriatric patients. 
Enhanced bioavailability: Bioavailability of drugs is 
enhanced due to absorption from mouth, pharynx and 
esophagus. 
Rapid action: Fast onset of therapeutic action as tablet 
gets disintegrated rapidly along with quick dissolution and 
absorption in oral cavity. 
Patient compliance: No need of water to swallow the 
dosage form. Hence, it is convenient for patients who are 
traveling and do not have immediate access to water. 
Ease of administration: Convenient to administer 
specially for geriatric, pediatric, mentally disabled and bed 
ridden patients who have difficulty in swallowing. 
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Obstruction free: No risk of suffocation in airways 
due to physical obstruction when swallowed, thus 
providing improved safety and compliance. 
Enhanced palatability: Good mouth feels, especially 
for pediatric patients as taste masking technique is used to 
avoid the bitter taste of drug. 
Simple packaging: No specific packaging required. It 
can be packaged in push through blisters. 
Business Avenue: Provide new business opportunities 
in the form of product differentiation, line extension, 
uniqueness and life cycle management. 
Cost effective: Conventional processing and 
packaging equipments allow the manufacturing of tablets 
at low cost. 
Ideal Properties of MDTs
 4
 
They should: 
 Not require water to swallow, but it should dissolve or 
disintegrate in the mouth in matter of seconds. 
 Be compatible with taste masking. 
 Be portable without fragility concern. 
 Have a pleasant mouth feel. 
 Leave minimum or no residue in the mouth after oral 
administration. 
 Exhibit low sensitive to environmental condition as 
temperature and humidity. 
 Allow the manufacture of the tablet using conventional 
processing and packaging equipments at low cost. 
 
Challenges in formulating Fast dissolving tablets: 5,19 
Palatability  
As most drugs are unpalatable, FDTs usually contain the 
medicament in a taste-masked form. Upon administration, 
it disintegrate or dissolve in patient‟s oral cavity, thus 
releasing the active ingredients which come in contact with 
the taste buds.Hence, taste-masking of the drugs becomes 
critical to patient compliance . 
Mechanical strength  
In order to allow FDTs to disintegrate in the oral cavity, 
they are made of either very porous and soft-molded 
matrices or compressed into tablets with very low 
compression force, which makes the  tablets friable and/or 
brittle, difficult to handle, andoften requiring specialized 
peel-off blister packing that may add to the cost. Only 
Wow tab and durasolv technologies can produce tablets 
that are sufficiently hard and durable to allow them to be 
packaged in multi-dose bottles. 
Hygroscopicity  
Several orally disintegrating dosage forms are hygroscopic 
and cannot maintain physical integrity under normal 
conditions of temperature and humidity. Hence, they need 
protection from humidity which calls for specialized 
product packaging. 
Amount of drug  
The application of technologies used for FDTs is limited 
by the amount of drug that can be incorporated into each 
unit dose. For lyophilized dosage forms, the drug dose 
must be less than 400 mg for insoluble drugs and 60 mg 
for soluble drugs. This parameter is particularly 
challenging when formulating a fast-dissolving oral films 
or wafers. 
Aqueous solubility  
Water-soluble drugs pose various formulation challenges 
because they form eutectic mixtures, which result in 
freezing-point depression and the formation of a glassy 
solid that may collapse upon drying because of loss of 
supporting structure during the sublimation process. Such 
collapse sometimes can be prevented by using various 
matrix-forming excipients such as mannitol that can induce 
crystallinity and hence, impart rigidity to the amorphous 
composite. 
 Size of tablet  
The ease of administration of a tablet depends on its size. 
It has been reported that the easiest size of tablet to 
swallow is 7-8 mm while the easiest size  to handle was 
one larger than 8 mm. Therefore, the tablet size that is both 
easy to take and easy to handle is difficult to achieve. 
FORMULATION OF MDTs:
5,6,7,8 
Drug:  
The ultimate characteristics of a drug for dissolution in the 
mouth and pre gastric absorption from MDTs include: 
 Free from bitter taste 
 Dose lower than 20 mg 
 Small to Moderate molecular weight 
 Good solubility in saliva 
 Ability to permeate through oral mucosal tissue 
 
Bulking materials:  
Bulking materials are significant in the formulation of fast-
melting tablets. The material contributes functions of a 
diluent, filler and cost reducer. Bulking agents improve the 
textural characteristics that in turn enhance the 
disintegration in the mouth, besides; adding bulk also 
reduces the concentration of the active in the composition. 
The recommended bulking agents for this delivery system 
should be more sugar-based such as mannitol, 
polydextrose, lactitol, DCL (direct compressible lactose) 
and starch hydrolystate for higher aqueous solubility and 
good sensory perception. Bulking agents are added in the 
range of 10 percent to about 90 percent by weight of the 
final composition. 
Emulsifying agents:  
Emulsifying agents are important excipients for 
formulating fast-melting tablets they aid in rapid 
disintegration and drug release without chewing, 
swallowing or drinking water. In addition, incorporating 
emulsifying agents is useful in stabilizing the immiscible 
blends and enhancing bioavailability. A wide range of 
emulsifiers is recommended for fast-tablet formulation, 
including alkyl sulfates, propylene glycol esters, lecithin, 
sucrose esters and others. These agents can be incorporated 
in the range of 0.05 percent to about 15 percent by weight 
of the final composition.  
Lubricants: 
Lubricants, though not essential excipients, can further 
assist in making these tablets more palatable after they 
disintegrate in the mouth. Lubricants remove grittiness and 
assist in the drug transport mechanism from the mouth 
down into the stomach. 
Flavours and sweeteners:  
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Flavours and taste-masking agents make the products more 
palatable and pleasing for patients. The addition of these 
ingredients assists in overcoming bitterness and 
undesirable tastes of some active ingredients.  
Superdisintegrants:  
A disintegrant is an excipient, which is added to a tablet or 
capsule blend to aid in the breakup of the compacted mass 
when it is put into a fluid environment.
 
Table 1: Enlists various existing superdisintegrants and also their mechanism of action 
 
Name of disintegrant Brand name Concentration (%) Mechanism of action 
Sodium Starch Glycolate Explotab,Primogel 2-8% Swelling 
Micro crystalline cellulose Avicel, Celex 2-15% Water wicking 
Cross linked povidone Cross povidone 2-5% Swelling, Water wicking 
Low substuted hydroxy 
propyl cellulose 
LH-11, LH-12 (Grades) 
 
1-5% Sweling 
Crosscarmellose sodium Ac-Di-Sol 1-3%Direct compression 
2-4% wet granulation 
Wicking and swelling 
Pregelatinized starch Starch 1500 1-20% Swelling 
 
Advantages: 1. Effective in lower concentrations. 
                      2. Less effect on compressibility and 
flowability. 
SELECTION OF SUPERDISINTEGRANTS: 
Although superdisintegrants primarily affect the rate of 
disintegration, but when used at high levels they can also 
affect mouth feel, tablet hardness and friability. Hence, 
various ideal factors to be considered while selecting an 
appropriate superdisintegrants for a particular 
formulationshould: 
• Produce rapid disintegration, when tablet comes in 
contact with saliva in the mouth/oral cavity. 
• Be compactable enough to produce less friable tablets. 
• Produce good mouth feel to the patients. Thus, small 
particle size is preferred to achieve patient compliance. 
• Have good flow, since it improves the flow 
characteristics of total blend. 
Various manufacturing techniques for MDDDS 
include: 
 Lyophilization 
 Moulding 
 Direct Compression 
 Cotton Candy Process 
 Spray Drying 
 Sublimation 
 Mass Extrusion 
 Nanonization 
 Fast Dissolving Films 
Freeze-Drying or Lyophilization
4 ,9,10
 
In freeze-drying process, the water is sublimed from the 
product after it is frozen. Zydis technology (ZT) is a 
patented technique, which had been used for drugs like 
famotidine, loperamide, piroxicam, oxazepam, lorazepam, 
domeperidone, brompheniramine, olanzepine, ondansetron 
and rizatriptan. Thirteen products are currently available in 
the market, which had been manufactured using this 
technology. In U.S., the MDT products available are: 
Claritin Reditab, Dimetapp Quick Dissolve, Feldene Melt, 
Maxalt- MLT, Pepcid RPD, Zofran ODT and Zyprexa 
Zydis. In the worldwide market, Zydis formulations are 
also available for oxazepam, lorazepam, loperamide, and 
enalapril. ZT utilizes a unique freeze-drying process to 
manufacture finished dosage units which significantly 
differ from conventional oral systems.  
The process involves the following steps: 
Stage 1 - bulk preparation of an aqueous drug solution or 
suspension and its subsequent precise dosing into pre-
formed blisters. It is the blister that actually forms the 
tablet shape and is, therefore, an integral component of the 
total product package. 
Stage 2 - passing the filled blisters through a specially 
designed cryogenic freezing process to control the ultimate 
size of the ice crystals which ensures that the tablets 
possess a porous matrix to facilitate the rapid 
disintegration property. These frozen units are then 
transferred to large-scale freeze dryers for the sublimation 
process, where the majority of the remaining moisture is 
removed from the tablets. 
Stage 3 - Sealing the open blisters using a heat-seal 
process to ensure stability and protection of the product 
from varying environmental conditions. 
 
Lyoc Lyoc technology lyophilizes, or “freeze-dries” an 
aqueous solution, suspension, or emulsion of an API and 
excipients. Lyoc‟s high degree of porosity yields shorter 
disintegration times than compressed tablets. The Lyoc 
manufacturing process produces a stable product without 
use of additives, preservatives or gelatins. This process is 
environmentally friendly and cost-effective because it 
doesn‟t require organic solvents. Lyoc technology is 
compatible with CIMA taste-masking techniques, 
customized release, high dosing and fixed-dose 
combination products. 
Quicksolv
9,10 is a porous solid form obtained by freezing 
an aqueous dispersion/solution of the drug containing 
matrix and then drying it by removing the water using 
excess of alcohol (solvent extraction). The final form 
disintegrates very rapidly but is limited to low drug content 
and can be used only for those drugs that are insoluble in 
the extraction solvent. The ideal drug characteristics 
required for this technology are relative low aqueous 
solubility, fine particle size < 50 μm and good aqueous 
stability in the suspension. 
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Advantages 
The major advantage of using this technique is that the 
tablets produced by this technology have very low 
disintegration time and have great mouthfeel due to fast 
melting effect. 
Disadvantages 
Although being a fairly routine process, lyophilization has 
some disadvantages like it is a relatively expensive and 
time consuming process. Furthermore, the product 
obtained is poorly stable and fragile, rendering 
conventional packaging unsuitable. 
 
       
Figure 5: Lyophilization Technology. Patented technology based on this process is Zydis technology 
 
Tablet Moulding
9,11
 
Moulded tablets invariably contain water-soluble 
ingredients due to which the tablets dissolve completely 
and rapidly. Following are the different tablet moulding 
techniques: 
Compression Moulding Process 
This manufacturing process involves moistening the 
powder blend with a hydroalcoholic solvent followed by 
pressing into mould plates to form a wetted mass 
(compression moulding). The solvent is then removed by 
air drying, a process similar to the manufacture of tablet 
triturates. Such tablets are less compact than compressed 
tablets and possess a porous structure that hastens 
dissolution. 
Heat-Moulding Process 
Heat-moulding process involves setting the molten mass 
containing a dispersed drug. This process uses agar 
solution as a binder and a blister packaging well as a 
mould to manufacture the tablet. A suspension containing 
drug, agar and sugar is prepared followed by pouring the 
suspension into the blister packaging well, solidifying the 
agar solution at room temperature to form a jelly and 
finally drying at approximately 30 °C under vacuum. 
Moulding by Vacuum Evaporation without 
Lyophilization  
This process involves pouring of the drug excipient 
mixture (in the form of a slurry or paste) into a mould of 
desired dimension, freezing the mixture to form a 
solidified matrix and finally subjecting it to vacuum drying 
at a temperature within the range of its collapse 
temperature and equilibrium freezing temperature. This 
results in the formation of a partially collapsed matrix. 
This method differs from the lyophilization technique, as 
in the former the evaporation of free unbound solvent 
occurs from a solid through the liquid phase to a gas, under 
controlled conditions, instead of the sublimation which 
takes place in the latter process.  
Direct Compression (DC)
[9,10,11]
 
DC is the simplest and most cost effective tablet 
manufacturing technique for MDTs as they can be 
fabricated using conventional tablet manufacturing and 
packaging machinery and also due to availability of 
tabletting excipients with improved flow, compressibility 
and disintegration properties, especially tablet 
disintegrants, effervescent agents and sugarbased 
excipients.
 
Table 2: Ideal Requirements, Advantages and Limitations of Direct Compression 
S.No Ideal requirements Advantages Limitations 
1 Flowability Cost effective production Segregation 
2. Compressibility Better stability of API Variation in functionality 
3. Dilution Potential Faster dissolution Low dilution potential 
4. Reworkability Less wear and tear of punches Reworkability 
5. Stability Simple validation Poor compressibility of API 
6. Controlled Particle Size Low microbial contamination Lubricant sensitivity 
 
Disintegrants 
In many MDT products based on DC process, the 
disintegrants mainly affect the rate of disintegration and 
hence dissolution which is further enhanced in the 
presence of water soluble excipients and effervescent 
agents. The introduction of superdisintegrants has 
increased the popularity of this technology. Tablet 
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disintegration time can be optimized by focusing on the 
disintegrant concentration. 
Below a critical disintegrant concentration, tablet 
disintegration time becomes inversely proportional to 
disintegrant concentration. However, above the critical 
concentration level of disintegrant, disintegration time 
remains approximately constant or the decrease is 
insignificant. 
Another DC based technology; Flashtab contains coated 
crystals of drug and microgranules alongwith disintegrants. 
In this technology, two types of disintegrants are used: a 
disintegrating agent (e.g., modified cellulose), which has a 
high swelling force and a swelling agent (e.g., starch) 
which has a low swelling force. Bi et al. and Watanbe used 
microcrystalline cellulose (MCC) and low substituted 
hydroxypropyl cellulose (HPC) to manufacture MDTs 
wherein the ratio of MCC to HPC varied from 8:2 to 9:1. 
Ito and Sugihara investigated the application of agar 
powder as a disintegrant due to its property of absorbing 
water and considerable swelling without forming a gel at 
physiological temperature. 
Effervescent Agents 
The evolution of CO2 as a disintegrating mechanism forms 
the basis of the patented Orasolv technology (OT) and is 
frequently used to develop over-the-counter formulations. 
The product contains microparticles and is slightly 
effervescent in nature. Saliva activates the effervescent 
agent which causes the tablet to disintegrate. The OT had 
been utilized in fabrication of six marketed products: four 
Triaminic Softchew formulations, Tempra FirsTabs and 
Remeron SolTab. 
Sugar-Based Excipients 
Another approach to manufacture MDTs by DC is the use 
of sugar-based excipients (e.g., dextrose, fructose, isomalt, 
lactitol, maltitol, maltose, mannitol, sorbitol, starch 
hydrolysate, polydextrose and xylitol) which display high 
aqueous solubility and sweetness and hence, imparts taste 
masking and a pleasing mouth feel. 
Mizumoto et al., have classified sugar-based excipients 
into two types based on their mouldability and dissolution 
rate. 
Type I saccharides (e.g., lactose and mannitol) exhibit low 
mouldability but high dissolution rate. 
Type II saccharides (e.g., maltose and maltitol) exhibit 
high mouldability but low dissolution rate 
Mouldability is defined as the capacity of the compound to 
be compressed/ moulded and to dissolve. It does not refer 
to the formation of a true mould by melting or solvent 
wetting process. The mouldability of Type I saccharide can 
be improved by granulating it with a Type II saccharide 
solution. 
The above technology forms the basis of WOWTAB 
which involves the use of fluidized bed granulation for the 
surface treatment of Type I saccharide with Type II 
saccharide. This technique has been used in the production 
of Benadryl Fast melt tablets. Here, two different types of 
saccharides are combined to obtain a tablet formulation 
with adequate hardness and fast dissolution rate.  
Cotton Candy Process
3,11,12
 
The FLASHDOSE® is a MDDDS manufactured using 
Shearform™ technology in association with Ceform TI™ 
technology to eliminate the bitter taste of the medicament. 
The Shearform technology is employed in the preparation 
of a matrix known as „floss‟, made from a combination of 
excipients, either alone or with drugs. The floss is a fibrous 
material similar to cotton-candy fibers, commonly made of 
saccharides such assucrose, dextrose, lactose and fructose 
at temperatures ranging between 180–266 °F. However, 
other polysaccharides such as polymaltodextrins and 
polydextrose can be transformed into fibers at 30–40% 
lower temperature than sucrose. This modification permits 
the safe incorporation of thermolabile drugs into the 
formulation. The tablets manufactured by this process are 
highly porous in nature and offer very pleasant mouthfeel 
due to fast solubilization of sugars in presence of saliva.  
Spray-Drying
3,12
 
Allen et al., have used spray-drying for the production of 
MDTs. The formulations contained hydrolyzed and 
unhydrolyzed gelatin as a supporting agent for the matrix, 
mannitol as a bulking agent and sodium starch 
glycolate/croscaramellose as a disintegrant. Disintegration 
and dissolution were further enhanced by adding an acid 
(e.g., citric acid) or an alkali (e.g., sodium bicarbonate). 
The suspension of above excipients was spray-dried to 
yield a porous powder which was compressed into tablets. 
Tablets manufactured by this method disintegrated in < 20 
secs in an aqueous medium. 
Sublimation
13,19
 
Sublimation has been used to produce MDTs with high 
porosity. A porous matrix is formed by compressing the 
volatile ingredients alongwith other excipients into tablets, 
which are finally subjected to a process of sublimation. 
Inert solid ingredients with high volatility (e.g., 
ammonium bicarbonate, ammonium carbonate, benzoic 
acid, camphor, hexamethylene tetramine, naphthalene, 
phthalic anhydride, urea and urethene) have been used for 
this purpose. Solvents such as cyclohexane and benzene 
were also suggested for generating the porosity in the 
matrix. Makino et al., reported a method using water as a 
pore-forming material. 
 
Figure 6: Sublimation technique. Evaporation of volatile agent 
results in formation of porous tablets thereby causing fast 
disintegration 
Mass-Extrusion
17
 
This technology involves softening of the active blend 
using the solvent mixture of water soluble polyethylene 
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glycol and methanol and expulsion of softened mass 
through the extruder or syringe to get a cylindrical shaped 
extrude which are finally cut into even segments using 
heated blade to form tablets. This process can also be used 
to coat granules of bitter drugs to mask their taste. 
Nanonization
17
 
A recently developed Nanomelt technology involves 
reduction in the particle size of drug to nanosize by milling 
the drug using a proprietary wet-milling technique. The 
nanocrystals of the drug are stabilized against 
agglomeration by surface adsorption on selected 
stabilizers, which are then incorporated into MDTs. This 
technique is especially advantageous for poorly water 
soluble drugs. Other advantages of this technology include 
fast disintegration/dissolution of nanoparticles leading to 
increased absorption and hence higher bioavailability and 
reduction in dose, cost effective manufacturing process, 
conventional packaging due to exceptional durability and 
wide range of doses (up to 200 mg of drug per unit). 
Fast Dissolving Films
19
 
It is a new frontier in MDDDS that provides a very 
convenient means of taking medications and supplements. 
In this technique, a non-aqueous solution is prepared 
containing water soluble film forming polymer (pullulan, 
carboxy methylcellulose, hydroxypropyl methylcellulose, 
hydroxyl ethylcellulose, hydroxyl propylcellulose, 
polyvinyl pyrrolidone, polyvinyl alcohol or sodium 
alginate, etc.), drug and other taste masking ingredients, 
which is allowed to form a film after evaporation of 
solvent. In case of a bitter drug, resin adsorbate or coated 
microparticles of the drug can be incorporated into the 
film. This film, when placed in mouth, melts or dissolves 
rapidly, releasing the drug in solution or suspension form. 
The features of this system include paper thin films of size 
less than 2X2 inches, dissolution in 5 sec, instant drug 
delivery and flavoured after taste. 
EVALUATION PARAMETERS: 
13,14,15,20,21
 
Weight variation test: Randomly selected 20 tablets were 
taken and their individual weights & the average weight of 
20 tablets were determined. The deviation of each 
individual tablet from the average weight was calculated 
and compared with the standard values given in 
Pharmacopoeia. 
 The % weight variation of each individual tablet from the 
average weight is calculated by the given formula 
 % 𝑊𝑒𝑖𝑔ℎ𝑡𝑉𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛
=
Individual weight of each tablet − Average weight of 20 tablets 
Average weight of 20 tablets
× 100 
Hardness test: Hardness of the tablets was measured by 
using hardness testers like Monsanto hardness tester, 
Pfizer hardness tester etc. The pressure required to break 
the tablets is measured as a function of hardness ( kg/ cm2 
). The values obtained must meet the standard value. 
Friability: Friability is to measure the extent of tablet 
breakage during physical stress conditions like Packing, 
transportation etc. A sample of randomly selected 6 tablets 
was evaluated for friability using Roche friabilator at 25 
rpm for 4 minutes. The % weight loss is calculated by 
measuring the total weight of 6 tablets before and after 
operation. Formula for calculating the % weight loss is 
given below:  
 % 𝑊𝑒𝑖𝑔ℎ𝑡 𝑙𝑜𝑠𝑠
=
Total weight of tablet before − Total weight of tablets after  
Total weight of tablets
× 100 
Wetting time: 
Wetting time and water absorption ratio are the significant 
parameters for mouth dissolving tablets. The following 
method for calculating the wetting time of the tablet. A 
piece of filter paper (circularly cut) was placed in a small 
petri plate containing water soluble dye solution. Tablet 
was placed on the paper and the time required for complete 
wetting of the tablet was determined (Figure 7).Bi Y. et al. 
used a tissue paper folded twice and was placed in a small 
culture dish ( i.d = 6.5 cm) containing 6 ml of water. 
 
Figure 7: Wetting time of Mouth dissolving tablet. The time 
taken for appearance of dye colour on tablet is wetting time 
Water absorption ratio:  
Similar to the procedure followed in determination of 
wetting time (Figures 8). However, here the initial weight 
and the final weight (after complete wetting) of tablet were 
calculated and the water absorption ratio was calculated by 
given formula: 
𝑅 =
Wa− Wb
Wb
× 100 
Where, R is water absorption ratio, Wa and Wb are the 
weights of tablet before and after wetting respectively. 
 
Figure 8: Calculation of water absorption ratio for MDTs. 
Difference between intial and final weights of tablet is noted 
Water absorption 
Disintegration time: Disintegration time for randomly 
selected 6 tablets was measured using disintegration test 
apparatus. The average time required for disintegration 
was calculated and compared with standards.  
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Invitro dissolution studies: Randomly selected 6 tablets 
were subjected to drug release studies using USP 
dissolution apparatus, in dissolution medium volume of 
900 ml was used and a temperature of 37±0.5oC was 
maintained. 5 ml of the sample was collected for every 5 
minutes interval till 30 minutes and replaced with 5 ml of 
fresh buffer solution. The samples were filtered and 
suitably diluted and the drug assay was performed using 
UV spectrophotometer or HPLC system. The results were 
compared with standard values. 
Taste or mouth feel: Healthy human volunteers were used 
for evaluation of mouth feel of the tablet. One tablet was 
evaluated for its mouth feel. A panel of 5 members 
evaluate the mouth feel by time intensity method. Sample 
equivalent to 40 mg was held in mouth for 10 seconds and 
the opinion is rated by giving different score values. (0: 
good, 1: tasteless, 2: slightly bitter, 3: bitter, 4: awful). 
Stability studies: Various stability studies like accelerated 
stability study, intermediate and long term stability studies 
were done during preformulation. The sample was 
subjected to higher temperature or humidity or both, to 
know their impact on the stability of mouth dissolving 
tablet.  
Uniformity of dispersion: Two randomly selected tablets 
were kept in 100 ml water and stirred for two minutes. The 
dispersion was passed through 22 meshes. The tablets were 
considered to pass the test if no residue remains on the 
screen. 
Drugs to be promising in corporate in Mouth dissolving 
tablets
16,17,18,19 
There are no particular limitations as long as it is a 
substance which is used as a   pharmaceutical active 
ingredient. 
Analgesics and Anti-inflammatory Agents: 
Aloxiprin, Auranofin, Azapropazone, Benorylate, 
Diflunisal, Etodolac, Fenbufen, Fenoprofen 
Calcim, Flurbiprofen, Ibuprofen, Indomethacin, 
Ketoprofen, Meclofenamic Acid, Mefenamic 
Acid, Nabumetone, Naproxen, Oxaprozin, 
Oxyphenbutazone, Phenylbutazone, Piroxicam, Sulindac. 
Anthelmintics : 
Albendazole, Bephenium Hydroxynaphthoate, 
Cambendazole, Dichlorophen, Iverrnectin, Mebendazole, 
Oxarnniquine, Oxfendazole, Oxantel Embonate, 
Praziquantel, Pyrantel Embonate, Thiabendazole. 
Anti-Arrhythmic Agents: 
Amiodarone, Disopyramide, Flecainide Acetate, Quinidine 
Sulphate, 
Anti-bacterial Agents: 
Benethamine Penicillin, Cinoxacin, Ciprofloxacin, 
Clarithromycin, Clofazimine, Cloxacillin, 
Demeclocycline, Doxycycline, Erythromycin, 
Ethionamide, Imipenem, Nalidixic Acid, Nitrofurantoin, 
Rifampicin, Spiramycin, Sulphabenzamide, Sulphadoxine, 
Sulphamerazine, Sulphacetamide, Sulphadiazine, 
Sulphafurazole, Sulphamethoxazole, Sulphapyridine, 
Tetracycline, Trimethoprim. 
Anti-Fungal Agents: 
Amphotericin, Butoconazole Nitrate, Clotrimazole, 
Econazole Nitrate, Fluconazole, Fiucytosine, Griseofulvin, 
Itraconazole, Ketoconazole, Miconazole, Natamycin, 
Nystatin, Sulconazole Nitrate, Terbinafine, Terconazole, 
Tioconazole, Undecenoic Acid. 
Anti-Gout Agents: 
Allopurinol, Probenecid, Sulphinpyrazone. 
Anti-Hypertensive Agents: 
Amlodipine, Carvedilol, Benidipine, Darodipine, 
Dilitazem, Diazoxide, Felodipine, Guanabenz Acetate, 
Indoramin, Isradipine, Minoxidii, Nicardipine, Nifedipine, 
Nimodipine, 
Phenoxybenzamine, Prazosin, Reserpine, Terazosin. 
Anti-Malarials: 
Amodiaquine, Chloroquine, Chlorproguanil, Halofantrine, 
Mefloquine, Proguanil, Pyrimethamine, Quinine Sulphate. 
Anti-Migraine Agents: Dihydroergotamine Mesyiate, 
Ergotamine Tartrate, Methysergide Maleate, Pizotifen 
Maleate, Sumatriptan Succinate. 
Anti-Neoplastic Agents and Immunosuppressants: 
Aminoglutethimide, Amsacrine, Azathiopnne, Busulphan, 
Chlorambucil, Cyclosporin, Dacarbazine, Estramustine, 
Etoposide, Lomustine, Melphalan, Mercaptopurine, 
Methotrexate, Mitomycin, Mitotane, Mitozantrone, 
Procarbazine, Tamoxifen Citrate, Testolactone. 
Anti-Thyroid Agents: 
Carbimazole, Propylthiouracil. 
Nutritional Agents: 
Betacarotene, Vitamin A, Vitamin B 2 , Vitamin D, 
Vitamin E, Vitamin K. 
Opioid Analgesics: 
Codeine, Dextropropyoxyphene, Diamorphine, 
Dihydrocodeine, Meptazinol, Methadone, 
Morphine, Nalbuphine, Pentazocine. 
Oral Vaccines: 
Vaccines designed to prevent or reduce the symptoms of 
diseases of which the following is a 
Representative Influenza, Tuberculosis, Meningitis, 
Hepatitis, Whooping Cough, Polio, Tetanus, Diphtheria, 
Malaria, Cholera, Herpes, Typhoid, HIV, Aids, Measles, 
Lyme Disease, Travellers Diarrhea, Hepatitis A, B And C, 
Otitis Media, Dengue Fever, Rabies, Parainfluenza, 
Rubella, Yellow Fever, Dysentery, Legionnaires Disease, 
Toxoplasmosis, Q-Fever, Haemorrhegic Fever, Argentina 
Haemorrhagic Fever, Caries, Chagas Disease, Urinary 
Tract Infection Caused By E.Coli, Pneumoccoccal 
Disease, Mumps, File://H:\Gits Mdt\Fast Dissolving Tablet 
The Future Of Compaction And Chikungunya. 
Proteins, Peptides and Recombinant Drugs: 
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Insulin (Hexameric/Dimeric/Monomeric Forms), 
Glucagon, Growth Hormone (Somatotropin), Polypeptides 
or Their Derivatives, (Preferably With A Molecular 
Weight from 1000 To 300,000), Calcitonins And Synthetic 
Modifications Thereof, Enkephalins, Interferons 
(Especially Alpha-2 Inter Feron For Treatment Of 
Common Colds). 
Sex Hormones: 
Clomiphene Citrate, Danazol, Ethinyloestradiol, 
Medroxyprogesterone Acetate, Mestranol, 
Methyltestosterone, Norethisterone, Norgestrel, Oestradiol, 
Conjugated Oestrogens, Progesterone, Stanozolol, 
Stiboestrol, Testosterone, Tibolone. 
CONCLUSION: 
The FDTs have potential advantages over conventional 
dosage forms, with their improved patient compliance, 
convenience, bioavailability and rapid onset of action had 
drawn the attention of many manufactures over a decade. 
FDTs formulations obtained by some of these technologies 
have sufficient mechanical strength, quick 
disintegration/dissolution in the mouth without water. 
There is a clear opportunity for new enhanced oral 
products arising within this market segment. 
Approximately one-third of the population, primarily the 
geriatric and pediatric populations, has swallowing 
difficulties, resulting in poor compliance with oral tablet 
drug therapy which leads to reduced overall therapy 
effectiveness.. These tablets are designed to dissolve or 
disintegrate rapidly in the saliva generally within <60 
seconds (range of 5- 50seconds). The development of a 
fast-dissolving tablet also provides an opportunity for a 
line extension in the marketplace, A wide range of drugs 
(e.g., neuroleptics, cardiovascular drugs, analgesics, 
antihistamines, and drugs for erectile dysfunction) can be 
considered candidates for this dosage form. As a drug 
entity nears the end of its patent life, it is common for 
pharmaceutical manufacturers to develop a given drug 
entity in a new and improved dosage form. A new dosage 
form allows a manufacturer to extend market exclusivity, 
while offering its patient population a more convenient 
dosage form or dosing regimen. 
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